US7097839B1
(en)
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
US6898532B1
(en)
|
1995-06-07 |
2005-05-24 |
Biomerieux, Inc. |
Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
|
US6429017B1
(en)
*
|
1999-02-04 |
2002-08-06 |
Biomerieux |
Method for predicting the presence of haemostatic dysfunction in a patient sample
|
US6321164B1
(en)
|
1995-06-07 |
2001-11-20 |
Akzo Nobel N.V. |
Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
|
US7030152B1
(en)
|
1997-04-02 |
2006-04-18 |
The Brigham And Women's Hospital, Inc. |
Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
|
US6727102B1
(en)
*
|
1997-06-20 |
2004-04-27 |
Leuven Research & Development Vzw |
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
|
US6502040B2
(en)
|
1997-12-31 |
2002-12-31 |
Biomerieux, Inc. |
Method for presenting thrombosis and hemostasis assay data
|
JP2002523782A
(ja)
*
|
1998-08-27 |
2002-07-30 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
不安定アンギナを診断するための方法および材料
|
US6309888B1
(en)
*
|
1998-09-04 |
2001-10-30 |
Leuven Research & Development Vzw |
Detection and determination of the stages of coronary artery disease
|
JP4486260B2
(ja)
*
|
1999-02-04 |
2010-06-23 |
バイオメリュー・インコーポレイテッド |
患者サンプルにおける止血機能不全の存在を予測するための方法および装置
|
AU782386C
(en)
*
|
1999-08-31 |
2006-08-10 |
Brigham And Women's Hospital |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
EP1520590A1
(en)
*
|
1999-08-31 |
2005-04-06 |
The Brigham and Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
EP1767223A1
(en)
*
|
1999-08-31 |
2007-03-28 |
The Brigham And Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
GB9929140D0
(en)
*
|
1999-12-10 |
2000-02-02 |
Univ Geneve |
Diagnostic assay for stroke
|
US7179612B2
(en)
*
|
2000-06-09 |
2007-02-20 |
Biomerieux, Inc. |
Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
WO2002038794A2
(en)
|
2000-11-09 |
2002-05-16 |
The Brigham And Women's Hospital, Inc. |
Cardiovascular disease diagnostic and therapeutic targets
|
ATE532070T1
(de)
*
|
2000-12-14 |
2011-11-15 |
Brigham & Womens Hospital |
Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
|
US6855509B2
(en)
*
|
2000-12-19 |
2005-02-15 |
Instrumentation Laboratory Company |
Protein S functional assay and kit therefor
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
BR0206273A
(pt)
|
2001-01-02 |
2006-11-21 |
Cleveland Clinic Foundation |
testes diagnósticos para caracterizar o risco de um paciente humano de desenvolver ou apresentar doença cardiovascular e para avaliar um agente terapêutico para doença cardiovascular em um sujeito suspeito de apresentar ou apresentando doença cardiovascular, e, kit
|
US6500630B2
(en)
|
2001-01-12 |
2002-12-31 |
Mayo Foundation For Medical Education And Research |
Marker for inflammatory conditions
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
ATE374641T1
(de)
*
|
2001-01-26 |
2007-10-15 |
Schering Corp |
Kombinationen vom ppar-aktivator fenofibrat mit dem hemmer der sterol-absorption ezetimibe zur behandlung von kardiovaskulären indikationen
|
CA2438899A1
(en)
*
|
2001-02-21 |
2002-09-06 |
Samuel D. Wright |
Method for determining efficacy of reverse cholesterol transport enhancing agents
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
US20040253637A1
(en)
*
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
US7713705B2
(en)
|
2002-12-24 |
2010-05-11 |
Biosite, Inc. |
Markers for differential diagnosis and methods of use thereof
|
US7608406B2
(en)
|
2001-08-20 |
2009-10-27 |
Biosite, Inc. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
ATE345793T1
(de)
*
|
2001-09-21 |
2006-12-15 |
Schering Corp |
Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
|
EP1451577A4
(en)
|
2001-11-05 |
2006-03-15 |
Brigham & Womens Hospital |
SOLUBLE CD40L (CD154) AS A PROGNOSEMARKER FOR ATHEROSCLEROSIS DISEASES
|
WO2003039349A2
(en)
*
|
2001-11-09 |
2003-05-15 |
Medstar Research Institute |
Method of using physiological markers to estimate cardiovascular risk
|
US20030144219A1
(en)
|
2001-11-15 |
2003-07-31 |
Phinney Stephen Dodge |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
US20040071633A1
(en)
*
|
2002-02-19 |
2004-04-15 |
Wright Samuel D. |
Method for determining efficacy of reverse cholesterol transport enhancing agents
|
CN102533972B
(zh)
|
2002-05-09 |
2014-07-02 |
布赖汉姆妇女医院 |
作为心血管病的标志和治疗靶的1l1rl-1
|
US7723327B2
(en)
*
|
2002-07-29 |
2010-05-25 |
Cardax Pharmaceuticals, Inc. |
Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
|
US20050009788A1
(en)
*
|
2002-07-29 |
2005-01-13 |
Lockwood Samuel Fournier |
Carotenoid ester analogs or derivatives for controlling connexin 43 expression
|
US7375133B2
(en)
*
|
2002-07-29 |
2008-05-20 |
Cardax Pharmaceuticals, Inc. |
Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
|
US7521584B2
(en)
*
|
2002-07-29 |
2009-04-21 |
Cardax Pharmaceuticals, Inc. |
Carotenoid analogs or derivatives for the inhibition and amelioration of disease
|
US20050049248A1
(en)
*
|
2002-07-29 |
2005-03-03 |
Lockwood Samuel Fournier |
Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
|
US7345091B2
(en)
*
|
2002-07-29 |
2008-03-18 |
Cardax Pharmaceuticals, Inc. |
Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
|
CA2495167C
(en)
*
|
2002-07-29 |
2018-08-21 |
Hawaii Biotech, Inc. |
Structural carotenoid analogs for the inhibition and amelioration of disease
|
US7320997B2
(en)
*
|
2002-07-29 |
2008-01-22 |
Cardax Pharmaceuticals, Inc. |
Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
|
US20050143475A1
(en)
*
|
2002-07-29 |
2005-06-30 |
Lockwood Samuel F. |
Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
|
US7763649B2
(en)
*
|
2002-07-29 |
2010-07-27 |
Cardax Pharmaceuticals, Inc. |
Carotenoid analogs or derivatives for controlling connexin 43 expression
|
US20050004235A1
(en)
*
|
2002-07-29 |
2005-01-06 |
Lockwood Samuel Fournier |
Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
|
US20050059635A1
(en)
*
|
2002-07-29 |
2005-03-17 |
Lockwood Samuel Fournier |
Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
|
US20050026874A1
(en)
*
|
2002-07-29 |
2005-02-03 |
Lockwood Samuel Fournier |
Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
|
US20050059659A1
(en)
*
|
2002-07-29 |
2005-03-17 |
Lockwood Samuel Fournier |
Carotenoid analogs or derivatives for controlling C-reactive protein levels
|
US20050148517A1
(en)
*
|
2002-07-29 |
2005-07-07 |
Lockwood Samuel F. |
Carotenoid ether analogs or derivatives for controlling connexin 43 expression
|
CA2499501A1
(en)
|
2002-09-27 |
2004-04-08 |
Martek Biosciences Corporation |
Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US7507531B2
(en)
*
|
2002-10-17 |
2009-03-24 |
Decode Genetics Chf. |
Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
|
US7851486B2
(en)
*
|
2002-10-17 |
2010-12-14 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
|
US20040097433A1
(en)
*
|
2002-11-15 |
2004-05-20 |
Sekhar Boddupalli |
Chroman derivatives for the reduction of inflammation symptoms
|
JP2006515294A
(ja)
*
|
2002-12-12 |
2006-05-25 |
アクティブバイオティクス インコーポレイティッド |
アテローム性動脈硬化症およびその関連疾患を治療または予防するための方法および試薬
|
US20050026168A1
(en)
*
|
2002-12-13 |
2005-02-03 |
Genesis Group Inc. |
Method for the detection of risk factors associated with myocardial infarction
|
GB0229747D0
(en)
*
|
2002-12-20 |
2003-01-29 |
Axis Shield Asa |
Assay
|
EP1601669B1
(en)
*
|
2003-03-07 |
2008-12-24 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ES2311806T3
(es)
*
|
2003-03-07 |
2009-02-16 |
Schering Corporation |
Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
US20040192660A1
(en)
*
|
2003-03-12 |
2004-09-30 |
Mullally John P. |
Protocol for improving vision
|
CA2518409A1
(en)
*
|
2003-03-12 |
2004-09-23 |
John P. Mullally |
Composition and method for treating inflammations by reducing c-reactive protein
|
US20050026979A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Maha Ghazzi |
Methods for treating inflammation and inflammation-associated diseases with a statin and ether
|
CA2539276A1
(en)
*
|
2003-09-17 |
2005-03-31 |
Decode Genetics Ehf. |
Methods of preventing or treating recurrence of myocardial infarction
|
JP2007518062A
(ja)
*
|
2003-09-29 |
2007-07-05 |
バイオサイト インコーポレイテッド |
敗血症を診断する方法および診断するための組成物
|
US20080085329A1
(en)
*
|
2003-10-22 |
2008-04-10 |
Fred Hutchinson Cancer Research Center, Inc. |
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
|
WO2005046675A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Jordan Holtzman |
Methods for enhancing glutathione peroxidase activity
|
PL1694342T3
(pl)
*
|
2003-11-12 |
2021-07-05 |
Trustees Of The University Of Pennsylvania |
Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
|
US9408891B2
(en)
*
|
2003-11-12 |
2016-08-09 |
The Trustees Of The University Of Pennsylvania |
Methods of using gelsolin to treat or prevent bacterial sepsis
|
EP2306192B1
(en)
|
2003-12-05 |
2015-10-14 |
The Cleveland Clinic Foundation |
Risk Markers For Cardiovascular Disease
|
US20080279843A1
(en)
*
|
2003-12-09 |
2008-11-13 |
Essential Skincare, Llc |
Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
US20050181451A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Bates Harold M. |
Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
|
US20050250745A1
(en)
*
|
2004-02-25 |
2005-11-10 |
Seddon Johanna M |
Biomarkers for age-related macular degeneration (AMD)
|
WO2005102356A1
(en)
*
|
2004-04-14 |
2005-11-03 |
Hawaii Biotech, Inc. |
Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
|
US20060058269A1
(en)
*
|
2004-04-14 |
2006-03-16 |
Lockwood Samuel F |
Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
|
PL1755661T3
(pl)
*
|
2004-05-12 |
2014-10-31 |
Brigham & Womens Hospital Inc |
Gelsolina do stosowania w leczeniu infekcji
|
CA2567223A1
(en)
|
2004-05-19 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Treatment of diseases associated with altered level of amyloid beta peptides
|
ES2571929T3
(es)
*
|
2004-05-26 |
2016-05-27 |
Region Nordjylland |
Procedimiento para determinar la cantidad de CD36 circulante
|
US8027791B2
(en)
|
2004-06-23 |
2011-09-27 |
Medtronic, Inc. |
Self-improving classification system
|
US8335652B2
(en)
|
2004-06-23 |
2012-12-18 |
Yougene Corp. |
Self-improving identification method
|
US20060020043A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Roger Berlin |
Methods and compositions for reducing C-reactive protein
|
WO2006020498A2
(en)
|
2004-08-11 |
2006-02-23 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
WO2006031592A1
(en)
*
|
2004-09-09 |
2006-03-23 |
University Of Massachusetts |
Disease markers for early stage atherosclerosis
|
AU2005284830A1
(en)
*
|
2004-09-13 |
2006-03-23 |
Lipomics Technologies, Inc. |
Metabolite markers for weight management
|
CA2624601C
(en)
*
|
2004-10-06 |
2018-07-03 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
EP1827472A4
(en)
*
|
2004-12-06 |
2012-09-05 |
Univ California |
METHOD FOR IMPROVING THE STRUCTURE AND FUNCTION OF ARTERIOLS
|
AU2006236150A1
(en)
*
|
2005-04-20 |
2006-10-26 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
MX2007013430A
(es)
*
|
2005-04-29 |
2008-03-19 |
Univ California |
Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
|
US20070099239A1
(en)
*
|
2005-06-24 |
2007-05-03 |
Raymond Tabibiazar |
Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
|
BRPI0707660A2
(pt)
*
|
2006-02-14 |
2011-05-10 |
Pola Chem Ind Inc |
cosmÉtico para clareamento da pele
|
WO2007106577A2
(en)
*
|
2006-03-15 |
2007-09-20 |
The Brigham And Women's Hospital, Inc. |
Gelsolin in the treatment and diagnosis of neurological disease
|
PT3279663T
(pt)
|
2006-03-15 |
2021-09-24 |
Brigham & Womens Hospital Inc |
Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
|
CA2650201C
(en)
|
2006-04-24 |
2020-10-20 |
James V. Snider |
Predicting mortality and detecting severe disease
|
ATE517341T1
(de)
*
|
2006-04-27 |
2011-08-15 |
Critical Care Diagnostics Inc |
Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
|
EP3059594A1
(en)
*
|
2006-05-01 |
2016-08-24 |
Critical Care Diagnostics, Inc. |
Prognosis of cardiovascular disease
|
PL2019965T3
(pl)
*
|
2006-05-02 |
2015-10-30 |
Critical Care Diagnostics Inc |
Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
|
EP2924440A3
(en)
|
2006-06-07 |
2016-03-09 |
Health Diagnostic Laboratory, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
AU2008213472A1
(en)
*
|
2007-02-05 |
2008-08-14 |
Aarhus Universitet |
A method for diagnosing atherosclerotic plaques by measurement of CD36
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
DK2682400T5
(da)
|
2007-08-28 |
2017-11-27 |
Uab Research Foundation |
Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
|
WO2009032722A1
(en)
*
|
2007-08-29 |
2009-03-12 |
The Cleveland Clinic Foundation |
Carbamylated proteins and risk of cardiovascular disease
|
US9423405B2
(en)
*
|
2007-12-05 |
2016-08-23 |
The Cleveland Clinic Foundation |
Trimethylamine compounds as risk predictors of cardiovascular disease
|
ES2634263T3
(es)
*
|
2008-01-25 |
2017-09-27 |
The General Hospital Corporation |
Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal
|
ES2590213T3
(es)
|
2008-04-18 |
2016-11-18 |
Critical Care Diagnostics, Inc. |
Predicción del riesgo a sufrir episodios cardíacos adversos graves
|
AU2009248057B2
(en)
*
|
2008-05-13 |
2013-02-21 |
Genmedica Therapeutics Sl |
Salicylate conjugates useful for treating metabolic disorders
|
WO2010014771A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Ore Pharmaceuticals Inc. |
Romazarit for treating metabolic diseases
|
US11835503B2
(en)
|
2009-05-28 |
2023-12-05 |
The Cleveland Clinic Foundation |
TMA-formation inhibitor treatment for elevated TMA-containing compound diseases
|
US10241093B2
(en)
|
2009-05-28 |
2019-03-26 |
The Cleveland Clinic Foundation |
Trimethylamine-containing compounds for diagnosis and prediction of disease
|
JP5379616B2
(ja)
|
2009-09-09 |
2013-12-25 |
株式会社日立製作所 |
粥状硬化性動脈硬化のマーカー因子と用途
|
CN102812359A
(zh)
*
|
2009-11-13 |
2012-12-05 |
Bg医药公司 |
心肌梗死的风险因子和预测
|
ES2750126T3
(es)
|
2011-03-17 |
2020-03-25 |
Critical Care Diagnostics Inc |
Procedimientos de predicción del riesgo de un resultado clínico adverso
|
US8708906B1
(en)
*
|
2011-09-07 |
2014-04-29 |
Allen J. Orehek |
Method for the prevention of dementia and Alzheimer's disease
|
WO2014031764A1
(en)
|
2012-08-21 |
2014-02-27 |
Critical Care Diagnostics, Inc. |
Multimarker risk stratification
|
US20160175360A1
(en)
*
|
2012-12-12 |
2016-06-23 |
Mesoblast, Inc. |
Treatment of diseases of endothelial dysfunction and inflammation
|
EP3140429B1
(en)
|
2014-05-05 |
2020-02-19 |
Medtronic Inc. |
Methods for scd, crt, crt-d, or sca therapy identification and/or selection
|
WO2016018665A1
(en)
|
2014-07-31 |
2016-02-04 |
Uab Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
WO2016040570A2
(en)
|
2014-09-12 |
2016-03-17 |
Children's Medical Center Corporation |
Dietary emulsion formulations and methods for using the same
|
FI127416B
(en)
*
|
2016-09-29 |
2018-05-31 |
Oy Medix Biochemica Ab |
Cardiovascular risk assessment method
|